Suppr超能文献

颅内出血患者行房颤导管消融术的安全性

Safety of catheter ablation for atrial fibrillation in patients with intracranial hemorrhage.

作者信息

Lin H, Li S-N, Bai R, Wen S-N, Liu N, Long D-Y, Yu R-H, Tang R-B, Sang C-H, Du X, Dong J-Z, Ma C-S

机构信息

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Beijing Anzhen Road, Chaoyang District, 100029, Beijing, China.

出版信息

Herz. 2018 Mar;43(2):169-176. doi: 10.1007/s00059-017-4551-8. Epub 2017 Mar 17.

Abstract

BACKGROUND

The safety of anticoagulation and radiofrequency catheter ablation (RFCA) in patients with atrial fibrillation (AF) and a history of intracranial hemorrhage (ICH) remains unclear. We investigated the risks and benefits of this approach in AF patients with a history of ICH.

PATIENTS AND METHODS

The ICH group included 45 AF patients with a history of ICH who underwent RFCA. Five of these patients were excluded because ICH occurred spontaneously after cerebral infarction. The control group included 80 individuals who presented for AF ablation and did not have a history of ICH. Two controls were matched for each study group patient in terms of sex, age (±2 years), type of AF, and procedure date.

RESULTS

Patients in the ICH group had higher CHADS (1.7 ± 1.3 vs. 1.1 ± 1.2, p < 0.05), CHADS-VASc (2.6 ± 1.7 vs. 1.9 ± 1.6, p < 0.05), and HAS-BLED scores (2.5 ± 1.0 vs. 1.1 ± 1.0, p < 0.001). All participants in both groups underwent successful RFCA. The incidence of ICH during follow-up (1 vs. 0, p = 0.333) was similar between the ICH and control groups. AF-free survival between the two groups was not significant (log-rank p = 0.283) within the first 3 months, but was significant (log-rank p = 0.011) within 48 months of RFCA. History of ICH was the only independent predictor of AF recurrence according to univariate Cox regression analysis.

CONCLUSION

In AF patients with a history of ICH, AF ablation with a standard anticoagulation strategy is safe and does not seem to be associated with an increased risk of hemorrhage.

摘要

背景

房颤(AF)合并颅内出血(ICH)病史患者的抗凝治疗及射频导管消融(RFCA)安全性尚不清楚。我们调查了这种治疗方法在有ICH病史的AF患者中的风险和益处。

患者与方法

ICH组包括45例有ICH病史并接受RFCA的AF患者。其中5例患者因脑梗死后自发性ICH被排除。对照组包括80例因AF消融就诊且无ICH病史的个体。根据性别、年龄(±2岁)、房颤类型和手术日期,为每个研究组患者匹配两名对照。

结果

ICH组患者的CHADS评分(1.7±1.3 vs. 1.1±1.2,p<0.05)、CHADS-VASc评分(2.6±1.7 vs. 1.9±1.6,p<0.05)和HAS-BLED评分(2.5±1.0 vs. 1.1±1.0,p<0.001)更高。两组所有参与者的RFCA均成功。ICH组和对照组随访期间ICH发生率相似(1例 vs. 0例,p=0.333)。两组间无房颤生存期在前3个月无显著差异(对数秩检验p=0.283),但在RFCA后48个月有显著差异(对数秩检验p=0.011)。根据单因素Cox回归分析,ICH病史是房颤复发的唯一独立预测因素。

结论

对于有ICH病史的AF患者,采用标准抗凝策略进行房颤消融是安全的,且似乎与出血风险增加无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验